Management
Dr. Claudia Lüske
Managing Director of the GmbH
Dr. Lüske initially studied Environmental Sciences at the Carl von Ossietzky University Oldenburg focusing on Marine Chemistry (Bachelor of Science). She performed her master’s degree in the field of “Toxicology“ at the Technical University of Kaiserslautern. During this study program, Dr. Lüske gained versatile insight into the pharmaceutical industry. This led her to the Immunotoxicology Department at the Bayer Health Care AG in Wuppertal for the conduct of her master’s thesis (Topic: Gene expression changes in rat lungs after inhalation of nanoparticles).
To perform her PhD at the University Medical Center Göttingen, she received a grant from the German Research Foundation. End of 2015 she completed her PhD in the field of “Molecular Medicine“, which shifted her focus to the field of Clinical Pharmacology, dealing with cancer research (Title: Molecular determinants for the outcome in gemcitabine-treated pancreatic cancer). The results of her PhD thesis were published in the prestigious Journal of the National Cancer Institute.
Afterwards, she continued to be employed as a research assistant at the University Medical Center Göttingen, for further research on pancreatic ductal adenocarcinoma.
Mrs. Lüske joined IPPMed in 2017, and has taken over the management in 2021.
Prof. Dr. Peter Bramlage, FESC, FACC
Shareholder of the GmbH
Dr. Bramlage began his medical training at the Justus-Liebig University in Gießen (Germany). His studies then took him to the Universities of Vienna (Austria) and Columbia (Missouri, USA). On returning from the USA, he completed his PhD at the Max Planck Institute for Physiological and Clinical Research, Bad Nauheim. From 1998 he worked at the Charite University Hospital, Berlin, in the Medical Clinic and the Outpatient Clinic for Cardiology and Angiology. In 2002 he switched his Focus into Clinical Pharmacology and Epidemiology, and since then, has held a number of positions at Sanofi Aventis and the Institute for Clinical Pharmacology at the TU Dresden.
During his time in Bad Nauheim, Dr Bramlage investigated the functional adaptation of cardiomyocytes to a variety of diseases that involve myocardial ischaemia. Since then, he has dealt with many topics in the fields of cardiovascular pharmacology and epidemiology. He has also recently been involved in major epidemiological studies concerning aortic stenosis, arterial hypertension, diabetes, and the metabolic syndrome, and in a series of clinical studies on the treatment of cardiovascular disease.
Dr Bramlage has published over 400 articles in peer-reviewed journals and is an active member of the League for the Fight Against High Blood Pressure and the German Society of Cardiology. He is also a Fellow of the European Society of Cardiology (FESC) and of the American College of Cardiology (FACC). He is a member of the Editorial Board of Expert Opinion on Pharmacotherapy.
Dr. Johannes Hankowitz
Partnership Dr. Bramlage & Dr. Hankowitz
Dr. Hankowitz studied pharmacy and philosophy with a focus on ethics, philosophy of science and structural research at the University of Münster and at the Max Planck Institute for Biochemistry in Martinsried near Munich. Dissertation at the Institute for Clinical Chemistry with the topic: Drug effects on the signal transduction of atherogenic processes. Subsequently, post doc fellowhship at the University Hospital Regensburg at the Institute for Clinical Chemistry with a focus on immunology and oncology.
While working, he obtained a Master of European Studies (M.E.S.) at RWTH Aachen University with a legal master’s thesis on pharmacovigilance. Changed to Sanofi Winthrop in the field of antihrombotics. Later Medical Director at Sanofi for Thrombosis, Cardiology and CNS and Director Medicine & Marketing Thrombosis and Cardiology. Then Head of the Medical & Pharmaceutical Division at Winthrop Arzneimittel GmbH and Member of the Executive Board. Mr. Hankowitz has held all AMG-relevant functions in the various functions such as Information Officer, Pharmacovigilance Officer, BTM Officer, Qualified Person, Sales Manager.
Mr Hankowitz is the editor of the AMNOG Monitor – an interactive analysis tool on all procedures of the early benefit assessment. In addition, he and his team developed the patent applied AMNOG Prediction and Pricing Tool, which uses artificial intelligence to predict the additional benefit and the reimbursement price to be negotiated on the basis of phase I/II studies.
Our partners
